Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - OXiGENE, INC. (NasdaqNM:OXGN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug 17Price hit new 52-week low ($2.56)
Location
321 Arsenal Street
Watertown, MA 02472
Phone: (617) 673-7800
Fax: (617) 924-9229
Employees (last reported count): 15
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 22%
·Institutional: 12% (15% of float)
(34 institutions)
·Net Inst. Buying: 7,000  shares (+0.53%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
OXiGENE, Inc. is an international biopharmaceutical development-stage company engaged principally in research into, and the development of products for use in, the treatment of cancer. OXiGENE has, in various stages of clinical development, therapeutic product candidates that derive from two principal technology platforms, the Combretastatin Platform and the Benzamide Platform. The Company's primary technology platform is based on Combretastatin. Combretastatin is a family of proprietary small-molecule, anti-tumor vascular targeting agents that destroy the existing blood vessels within, and to some extent the blood vessels leading to, a tumor, thereby stopping the growth of the tumor, shrinking it and preventing it from metastasizing. The benzamide platform was originally developed by the Company around inhibition of DNA repair processes. The third-generation benzamide is Declopramide (formerly Oxi-104), which makes tumor cells more susceptible to radiation damage and/or chemotherapy.
More from Market Guide: Expanded Business Description

Financial Summary
OXiGENE, Inc. is a development stage biopharmaceutical company engaged principally in the research into and the development of products for use in the treatment of cancer. For the six months ended 6/30/01, total revenues decreased 16% to $1.8 million. Net loss increased 36% to $5.9 million. Results reflect lower interest income, the absence of unrealized investment gains and increased general and administrative expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Bjorn Nordenvall, M.D., Ph.D., 49
Chairman, Pres, CEO
$300K
Frederick Driscoll, 50
Pres of Operations and Fin.
42K
David Chaplin, M.D., 45
COO and Head of R&D and Chief Scientific Officer
150K
David Sherris, M.D., Ph.D., 48
VP-R&D
264K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:OXGNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 17-Aug-2001
$2.56 
Recent Price$3.41 
52-Week High
on 12-Sep-2000
$12.00 
Beta1.28 
Daily Volume (3-month avg)15.6K
Daily Volume (10-day avg)22.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-69.0%
52-Week Change
relative to S&P500
-58.4%
Share-Related Items
Market Capitalization$38.8M
Shares Outstanding11.4M
Float8.90M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.48 
Earnings (ttm)-$0.95 
Earnings (mrq)-$0.33 
Sales (ttm)$0.29 
Cash (mrq)$2.00 
Valuation Ratios
Price/Book (mrq)2.31 
Price/EarningsN/A 
Price/Sales (ttm)11.61 
Income Statements
Sales (ttm)$3.27M
EBITDA (ttm)-$10.3M
Income available to common (ttm)-$10.7M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-33.88%
Return on Equity (ttm)-49.08%
Financial Strength
Current Ratio (mrq)16.03 
Debt/Equity (mrq)0 
Total Cash (mrq)$22.8M
Short Interest
As of 8-Aug-2001
Shares Short371.0K
Percent of Float4.2%
Shares Short
(Prior Month)
370.0K
Short Ratio28.54 
Daily Volume13.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.